- Sixth Wave’s (SIXW) Accelerated Molecularly Imprinted Polymers (AMIPs) technology has been shown to be 250x more sensitive than rapid antigen COVID tests
- This means AMIPs can detect both symptomatic and asymptomatic carriers at a level approaching PCR tests
- The company is readying itself for clinical studies on the path to AMIPs’ regulatory approval in Canada and the U.S.
- Sixth Wave Innovations’ patented technologies extract and detect target substances at the molecular level
- Sixth Wave (SIXW) is up by 14.29 per cent trading at $0.08 per share
Sixth Wave (SIXW) has proven its AMIPs tech to be 250x more sensitive than rapid antigen COVID tests.
This means AMIPs can detect both symptomatic and asymptomatic carriers through saliva samples at a level approaching PCR tests.
Research was conducted at the world-renowned Li Ka Shing Institute of Virology at the University of Alberta.
AMIPs’ superior testing attributes also include faster results, non-invasive testing, reduced costs, inexpensive scaling and rapid development times for variants or new viral threats.
Sixth Wave is preparing for independent clinical testing for regulatory approval in Canada and the U.S.
“With the achievement of these new technical milestones, AMIPs is perfectly positioned to fill a market need by introducing a product that will bridge the gap between PCR and rapid antigen tests,” stated Jonathan Gluckman, CEO of Sixth Wave.
“The AMIPs technology promises to offer fast and accurate results from a non-invasive test at an affordable price. We have rapidly advanced this new technology platform from an abstract concept to a pre-market prototype that promises to contend with the entrenched technologies of the in vitro diagnostic market for COVID-19,” he added.
Sixth Wave Innovations’ patented technologies extract and detect target substances at the molecular level.
Sixth Wave (SIXW) is up by 14.29 per cent trading at $0.08 per share as of 2:21 pm EST.
